KR100975961B1 - ＰＰＡＲα활성화에 반응하는 질병의 치료에 유용한α－페닐티오카르복시산 및＄Ｇ（ａ）－페닐옥시－카르복시산의 유도체 - Google Patents

ＰＰＡＲα활성화에 반응하는 질병의 치료에 유용한α－페닐티오카르복시산 및＄Ｇ（ａ）－페닐옥시－카르복시산의 유도체 Download PDF

Info

Publication number
KR100975961B1
KR100975961B1 KR1020047010634A KR20047010634A KR100975961B1 KR 100975961 B1 KR100975961 B1 KR 100975961B1 KR 1020047010634 A KR1020047010634 A KR 1020047010634A KR 20047010634 A KR20047010634 A KR 20047010634A KR 100975961 B1 KR100975961 B1 KR 100975961B1
Authority
KR
South Korea
Prior art keywords
mmol
methyl
silica gel
room temperature
eluent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047010634A
Other languages
English (en)
Korean (ko)
Other versions
KR20040068996A (ko
Inventor
기안네씨파비오
나탈리나 델루오모
엠마누엘라 타쏘니
마리아 오르넬라 틴티
안나 플로라이나 스키아로니
모니카 밴데라
폼페오 페쏘토
알두이노 알두이니
Original Assignee
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. filed Critical 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Publication of KR20040068996A publication Critical patent/KR20040068996A/ko
Application granted granted Critical
Publication of KR100975961B1 publication Critical patent/KR100975961B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
KR1020047010634A 2002-01-15 2003-01-15 ＰＰＡＲα활성화에 반응하는 질병의 치료에 유용한α－페닐티오카르복시산 및＄Ｇ（ａ）－페닐옥시－카르복시산의 유도체 Expired - Fee Related KR100975961B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM02A000014 2002-01-15
IT2002RM000014A ITRM20020014A1 (it) 2002-01-15 2002-01-15 Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
PCT/IT2003/000011 WO2003059875A2 (en) 2002-01-15 2003-01-15 DERIVATIVES OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPARα ACTIVATION

Publications (2)

Publication Number Publication Date
KR20040068996A KR20040068996A (ko) 2004-08-02
KR100975961B1 true KR100975961B1 (ko) 2010-08-16

Family

ID=11455954

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047010634A Expired - Fee Related KR100975961B1 (ko) 2002-01-15 2003-01-15 ＰＰＡＲα활성화에 반응하는 질병의 치료에 유용한α－페닐티오카르복시산 및＄Ｇ（ａ）－페닐옥시－카르복시산의 유도체

Country Status (16)

Country Link
US (2) US20050054671A1 (enExample)
EP (1) EP1474387B1 (enExample)
JP (1) JP2005514456A (enExample)
KR (1) KR100975961B1 (enExample)
CN (1) CN100522940C (enExample)
AR (1) AR038146A1 (enExample)
AT (1) ATE489361T1 (enExample)
AU (1) AU2003209679B2 (enExample)
BR (1) BR0306824A (enExample)
CA (1) CA2472223A1 (enExample)
DE (1) DE60335083D1 (enExample)
IT (1) ITRM20020014A1 (enExample)
MX (1) MXPA04006803A (enExample)
PL (1) PL372666A1 (enExample)
TW (1) TW200305410A (enExample)
WO (1) WO2003059875A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
ITRM20020629A1 (it) * 2002-12-19 2004-06-20 Sigma Tau Ind Farmaceuti Uso di acidi alfa-feniltiocarbossilici e alfa-fenilossicarbossilici ad attivita' ipoglicemizzante e/o ipolipidemizzante.
DK1667964T3 (da) 2003-09-19 2009-10-26 Janssen Pharmaceutica Nv 4-((Phenoxyalkyl)thio)-phenoxyeddikesyrer og analoger
CN1867546A (zh) * 2003-10-28 2006-11-22 雷迪实验室有限公司 新颖化合物及其在药物中的用途、其制备方法以及含有它们的药物组合物
US7902367B2 (en) 2004-08-11 2011-03-08 Kyorin Pharmaceutical Co., Ltd. Cyclic amino benzoic acid derivative
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
FR2880886B1 (fr) * 2005-01-14 2007-04-06 Merck Sante Soc Par Actions Si Derives de l'acide 6-phenylhex-5-enoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
WO2006082495A1 (en) * 2005-02-02 2006-08-10 Ranbaxy Laboratories Limited Peroxisome proliferator activated receptor modulators
FR2882359A1 (fr) * 2005-02-24 2006-08-25 Negma Lerads Soc Par Actions S Derives activateurs de ppar, procede de preparation et application en therapeutique
WO2006101108A1 (ja) * 2005-03-23 2006-09-28 Kyorin Pharmaceutical Co., Ltd. 新規環状アミノフェニルアルカン酸誘導体
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
WO2008014430A1 (en) 2006-07-27 2008-01-31 Emisphere Technologies, Inc. Arylsulfanyl compounds and compositions for delivering active agents
JP5305818B2 (ja) * 2008-10-03 2013-10-02 キヤノン株式会社 生体情報取得装置
JP5669889B2 (ja) * 2013-06-27 2015-02-18 キヤノン株式会社 生体情報取得装置
CN106179111B (zh) * 2016-07-16 2018-08-14 江南大学 一种由羧酸盐阴离子表面活性剂和二聚季铵盐形成的粘弹溶液

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422679A (en) * 1972-11-16 1976-01-28 Funai Pharmaceutical Ind Ltd Substituted phenoxy-a-methylpropionic acid derivatives and a process for producing the same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1121722A (en) * 1966-03-31 1968-07-31 Ici Ltd New carboxylic acid derivatives
US3663540A (en) * 1970-06-19 1972-05-16 R & L Molecular Research Ltd 7 - (p-aminomethylphenylthio)acetamido-3 -(pyridiniummethyl)ceph - 3 - em - 4-carboxylate
US3965093A (en) * 1971-09-24 1976-06-22 E. R. Squibb & Sons, Inc. 6-Arylthio penicillanic acid and derivatives thereof
FR2285867A1 (fr) * 1974-09-30 1976-04-23 Lafon Labor Derives du diphenylsulfoxyde
DE2861187D1 (en) * 1977-07-07 1981-12-24 Ciba Geigy Ag Phenoxy-phenylsulfinyl-and-sulfonylalkanecarboxylic acid derivatives, method for their preparation and their use as herbicides and plant growth regulators.
JPH0311045A (ja) * 1989-06-08 1991-01-18 Hodogaya Chem Co Ltd ベンズアミド誘導体
JPH06234732A (ja) * 1992-09-10 1994-08-23 Banyu Pharmaceut Co Ltd 置換アセトアミド誘導体
FR2700166B1 (fr) * 1993-01-07 1995-02-17 Rhone Poulenc Rorer Sa Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
JP3583529B2 (ja) * 1995-12-04 2004-11-04 富士写真フイルム株式会社 ハロゲン化銀感光材料
EP0904079B1 (en) * 1996-02-02 2004-03-24 Merck & Co., Inc. Antidiabetic agents
AU4050797A (en) 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
US6197791B1 (en) * 1997-02-27 2001-03-06 American Cyanamid Company N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6294573B1 (en) * 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
CA2335288A1 (en) * 1998-06-22 1999-12-29 F. Hoffmann-La Roche Ag Propenyl cephalosporin derivatives
JP4618845B2 (ja) * 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
DE19940415A1 (de) * 1999-08-26 2001-03-08 Friedrich Spener Verzweigtkettige Fettsäuren als fettabbauende Wirkstoffe
US6525093B1 (en) * 1999-11-08 2003-02-25 Calyx Therapeutics Inc. Compounds to treat diabetes and associated conditions
KR20020090211A (ko) * 2000-01-28 2002-11-30 노보 노르디스크 에이/에스 알키닐 치환된 프로피온산 유도체 및 당뇨병 및 비만에대한 그것의 사용
WO2001079150A1 (en) * 2000-04-17 2001-10-25 Novo Nordisk A/S New compounds, their preparation and use
PT1285908E (pt) * 2000-05-29 2008-12-04 Kyorin Seiyaku Kk Derivados do ácido fenilpropiónico substituídos
CA2420178A1 (en) * 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422679A (en) * 1972-11-16 1976-01-28 Funai Pharmaceutical Ind Ltd Substituted phenoxy-a-methylpropionic acid derivatives and a process for producing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry, 1998, 41(7), pp. 1084-1091*
Journal of Medicinal Chemistry, 1999, 42(19), pp. 3785-3788*

Also Published As

Publication number Publication date
DE60335083D1 (de) 2011-01-05
CN1620429A (zh) 2005-05-25
US20080027098A1 (en) 2008-01-31
AR038146A1 (es) 2004-12-29
ATE489361T1 (de) 2010-12-15
EP1474387A2 (en) 2004-11-10
TW200305410A (en) 2003-11-01
WO2003059875A3 (en) 2003-12-04
AU2003209679A1 (en) 2003-07-30
EP1474387B1 (en) 2010-11-24
BR0306824A (pt) 2004-12-21
KR20040068996A (ko) 2004-08-02
ITRM20020014A1 (it) 2003-07-15
US20050054671A1 (en) 2005-03-10
WO2003059875A2 (en) 2003-07-24
JP2005514456A (ja) 2005-05-19
AU2003209679B2 (en) 2009-02-19
PL372666A1 (en) 2005-07-25
ITRM20020014A0 (it) 2002-01-15
CA2472223A1 (en) 2003-07-24
MXPA04006803A (es) 2004-10-11
CN100522940C (zh) 2009-08-05
HK1076625A1 (zh) 2006-01-20

Similar Documents

Publication Publication Date Title
KR100975961B1 (ko) ＰＰＡＲα활성화에 반응하는 질병의 치료에 유용한α－페닐티오카르복시산 및＄Ｇ（ａ）－페닐옥시－카르복시산의 유도체
US8461183B2 (en) PPAR agonist compounds, preparation and uses
TWI249522B (en) Compounds that modulate PPAR activity and methods for their preparation
KR100969979B1 (ko) 페닐（알킬）카르복시산 유도체 및 디이온성페닐알킬헤테로사이클릭 유도체, 및 혈청 글루코스및／또는 혈청 지질 강하 활성을 갖는 약제로서의 그의 용도
KR20110082145A (ko) 아릴 ｇｐｒ１２０ 수용체 작동약 및 이의 용도
MXPA04008176A (es) Derivado de acido fenilalcanoico sustituido y uso del mismo.
KR20050008661A (ko) 치환된 페닐아세트산
JPWO2002046176A1 (ja) ペルオキシソーム増殖剤応答性受容体の活性化剤
CA2620658A1 (fr) Nouveaux composes de l'indole
HUP0300857A2 (hu) Peroxiszóma proliferátor aktivált agonisták
CA2620662C (fr) Derives de pyrrolopyridine et leurs utilisations comme modulateurs des recepteurs ppar
KR100826108B1 (ko) 퓨란-2-카복실산 유도체 및 그의 제조 방법
EP1572180B1 (en) Use of alpha-phenylthiocarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity
KR101275770B1 (ko) ＰＰＡＲα/γ/δ 효능제로 작용하는 알콕시 인돌-3-아세트산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
KR20070053622A (ko) ＰＰＡＲγ와 ＰＰＡＲα의 활성을 항진시키는 신규화합물, 그것의 제조방법및 그것을 함유한 약제 조성물
WO2005105764A1 (en) Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications threreof
FR2827859A1 (fr) Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
HK1076625B (en) Derivatives of a-phenylthiocarboxylic and sg(a)-phenyloxy-carboxylic acids useful for the treatment of diseases responding to ppara activation
CN108003074A (zh) 联苯羧酸类化合物及其制备方法和用途
JP4220827B2 (ja) 安息香酸誘導体及びこれを含有する医薬
WO2011031111A2 (ko) P P A R α/γ/δ 효능제로 작용하는 알콕시 인돌-3-아세트산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20130810

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130810

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000